2019
DOI: 10.1080/01902148.2019.1621408
|View full text |Cite
|
Sign up to set email alerts
|

Inhaled salbutamol from aerolizer and diskus at different inhalation flows, inhalation volume and number of inhalations in both healthy subjects and COPD patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
19
0

Year Published

2020
2020
2025
2025

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 12 publications
(20 citation statements)
references
References 35 publications
1
19
0
Order By: Relevance
“…For those patients who cannot generate a high inhalation flow rate due to low lung capacity, it is recommended to inhale twice from the same dose. The in-vitro results from the present research are in accordance with the in-vivo study carried out by Boshra et al, (2019) that it is essential to inhale twice and as hard and deep as possible from each dose when using DPI especially with COPD-patients having poor inspiratory efforts such as elderly patients and children.…”
Section: Resultssupporting
confidence: 89%
“…For those patients who cannot generate a high inhalation flow rate due to low lung capacity, it is recommended to inhale twice from the same dose. The in-vitro results from the present research are in accordance with the in-vivo study carried out by Boshra et al, (2019) that it is essential to inhale twice and as hard and deep as possible from each dose when using DPI especially with COPD-patients having poor inspiratory efforts such as elderly patients and children.…”
Section: Resultssupporting
confidence: 89%
“…For the in vivo model using 12 subjects (healthy and COPD patients) and three DPIs, the input variables included; X1: DPI type as mentioned earlier, X2: subject type (4 L for healthy and 2 L for obstructive lung disease patients), X3: number of inhalations (1 or 2), X4: type of inhalations (10 seconds for slow and 5 seconds for fast) and X5: sampling time (0.5 hour and 24 hour). The output property Y1 was the percentage of excreted dose (lung or systemic bioavailability) 6,17 . Sampling time of 0.5 hour was indicative of lung bioavailability of the inhaled drug, while 24 hour cumulative samples were representative of the amount of the systemic bioavailability of the drug 25 …”
Section: Methodsmentioning
confidence: 99%
“…The optimum inhalation volume for the best aerosol delivery should be determined for each DPI. Guidelines for using different DPIs are available for optimising the emitted potion of aerosol 17,18 . Hence, DPI efficiency is highly dependent on the patient's inspiratory effort, formulation characteristics and inhalation technique.…”
Section: Introductionmentioning
confidence: 99%
“…Concerning RIF determination, data generating from each animal in terms of drug concentration were related to the drug loading corresponding to each administered sample. Moreover, since relationships between dosage emission and device flow-rate are well known [33][34][35], the actual inhaled dose per mouse was calculated by considering RIF amount not emitted by the device. The actual emission doses were ≥70% of those loaded inside the device (78.6 ± 3.3%, 69.3 ± 9.2%, 85.6 ± 5.4%, for SLNas/MS, SLNas/MS-ST, SLNas/ST, respectively) apart from SLNas/F127 with an emission dose of 53.4 ± 10.7% owing to its very poor flowability and high cohesiveness already highlighted in our previous work [17].…”
Section: In Vivo Studymentioning
confidence: 99%